HK/China Equity Long-Short

Osbert Tang, CFA

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/lung-fung-group-holdings-limited" target="_blank" data-smartkarma-citation="entities:46142:1" rel="noopener">Lung Fung Group (2290 HK)</a> is still 37.3% below its IPO price, despite a sharp rebound following its better-than-expected FY26 results. </li>
<li>Its same-store sales have consistently outperformed, and the start for 1Q FY27 appears encouraging. With an ROE of 72.7% for FY27, its 1.9x P/B is undemanding. </li>
<li>At a 4.8x FY27F PER and a 12.6% dividend yield, the stock is extremely cheap and trades at a steep discount to its HK-listed peers. </li>
</ul>



Lung Fung Group (2290 HK) is still 37.3% below its IPO price, despite a sharp rebound following its better-than-expected FY26 results. 
Its same-store sales have consistently outperformed, and the start for 1Q FY27 appears encouraging. With an ROE of 72.7% for FY27, its 1.9x P/B is undemanding. 
At a 4.8x FY27F PER and a 12.6% dividend yield, the stock is extremely cheap and trades at a steep discount to its HK-listed peers. 


Lung Fung Group (2290 HK): Still Looks Undervalued

Japanese Turnaround Situations, Short-Ideas, Azabu Research

Michael Allen

Japanese Turnaround Situations, Short-Ideas

Azabu Research

Azabu Research is a publishing and consulting firm focused on distressed equities in the Japanese market. We specialize in turnaround strategies, corporate combinations, divestitures, and restructuring.

Publisher of the Tokyo Turnaround Letter, which conducts the most thorough research possible of publicly available information, including forensic tests for fraudulent overstatement of assets and understatement of liabilities, as well as rigorous market and industry analysis to assess the underlying strengths of the company’s products or services, the appropriateness of the company’s turnaround strategy, and the skill of its current management team. The average length of a report exceeds 25 pages of text and tables, excluding any disclosures or executive summaries.

We have more than 30 years of experience in applying this process to distressed equities in Japan. Additionally, subscribers have free access to detailed, yet easily navigated earnings models for the target company as well as the top five comparable companies, and unlimited access to the analyst for follow-up questions.

Azabu Research also conducts be-spoke research on a project basis, and provides consulting services to companies looking to restructure, divest, make acquisitions, go public, or improve investor sentiment toward their stock.

Independent Research and Consulting Firm

<ul>
<li>Cosmos Pharmaceutical Corp (a drug store chain operator that sells mostly food) is scaling faster than peers, opening stores organically while maintaining unusually stable per-store operating profit.</li>
<li>Its food-led discount model creates high traffic, purchasing leverage, and a long runway in Japan’s fragmented packaged-food market.</li>
<li>Slow, secular decline in RoE is inevitable, but the market is discounting an unrealistically fast pace of decay. Cosmos still has a very long growth runway.</li>
</ul>


Cosmos Pharmaceutical Corp (a drug store chain operator that sells mostly food) is scaling faster than peers, opening stores organically while maintaining unusually stable per-store operating profit.
Its food-led discount model creates high traffic, purchasing leverage, and a long runway in Japan’s fragmented packaged-food market.
Slow, secular decline in RoE is inevitable, but the market is discounting an unrealistically fast pace of decay. Cosmos still has a very long growth runway.


Cosmos (3349): Still Miles of Growth Runway

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>
<a href="https://smartkarma.com/entities/cosmos-pharmaceutical-corp">Cosmos Pharmaceutical</a> showcases a robust growth trajectory, underpinned by an aggressive store expansion strategy and a resilient "Everyday Low Price"business model that resonates with consumers.</li>
  <li>The company's unique "small-catchment-area mega drugstore"strategy allows for high-density store rollouts, aiming for dominant regional market share, particularly in its home base of Kyushu.</li>
  <li>While revenue and net income growth are impressive, the company's strategy of rapid expansion results in significant capital expenditure, leading to consistently negative free cash flow, a key risk for investors to monitor.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Cosmos Pharmaceutical showcases a robust growth trajectory, underpinned by an aggressive store expansion strategy and a resilient "Everyday Low Price"business model that resonates with consumers.
  The company's unique "small-catchment-area mega drugstore"strategy allows for high-density store rollouts, aiming for dominant regional market share, particularly in its home base of Kyushu.
  While revenue and net income growth are impressive, the company's strategy of rapid expansion results in significant capital expenditure, leading to consistently negative free cash flow, a key risk for investors to monitor.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Cosmos Pharmaceutical (3349 JP) - Aug 2026

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/lung-fung-group-holdings-limited" target="_blank" data-smartkarma-citation="entities:46142:1" rel="noopener">Lung Fung Group (2290 HK)</a>, a leading Hong Kong-based chain retail store of beauty, health and pharmaceutical products, is seeking to raise HK$672m net proceeds.</li>
<li>When compared with <a href="https://www.smartkarma.com/entities/sa-sa-international-holdings-limited" target="_blank" data-smartkarma-citation="entities:20143:1" rel="noopener">Sa Sa (178 HK)</a>, it has higher operating and net margins, and also better net profit for FY27.  </li>
<li>At the high-end of IPO price range (HK$6.38), it trades on 9.2x FY27 PER. At par to Sa Sa's 12x, there will be a 29% upside potential to HK$8.25. </li>
</ul>



Lung Fung Group (2290 HK), a leading Hong Kong-based chain retail store of beauty, health and pharmaceutical products, is seeking to raise HK$672m net proceeds.
When compared with Sa Sa (178 HK), it has higher operating and net margins, and also better net profit for FY27.  
At the high-end of IPO price range (HK$6.38), it trades on 9.2x FY27 PER. At par to Sa Sa's 12x, there will be a 29% upside potential to HK$8.25. 


Lung Fung Group (2290 HK) IPO: Too Cheap to Ignore

Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>A month ago I wrote <a href="https://www.smartkarma.com/insights/japan-activism-m-a-closing-in-on-the-tsuruha-partial-tender-likely-needs-to-be-higher" target="_blank" data-smartkarma-citation="insights:206132" rel="noopener">[Japan Activism/M&amp;A] - Closing In On the Tsuruha Partial Tender - Likely Needs To Be Higher</a>. Now we are &lt;2wks to the deal.  </li>
<li>At the time, I said the Partial Tender Offer Price needed to be higher than the mooted ¥2,280. <a href="https://www.smartkarma.com/entities/tsuruha-holdings-inc" target="_blank" data-smartkarma-citation="entities:9536:1" rel="noopener">Tsuruha Holdings (3391 JP)</a> shares are up 10.0% in that month. </li>
<li>The three largest peers are -2.0% on average in that period. The average of 8 peers is +0.5%. I still expect the partial offer price needs to be near ¥3,100</li>
</ul>


A month ago I wrote [Japan Activism/M&amp;A] - Closing In On the Tsuruha Partial Tender - Likely Needs To Be Higher. Now we are &lt;2wks to the deal.  
At the time, I said the Partial Tender Offer Price needed to be higher than the mooted ¥2,280. Tsuruha Holdings (3391 JP) shares are up 10.0% in that month. 
The three largest peers are -2.0% on average in that period. The average of 8 peers is +0.5%. I still expect the partial offer price needs to be near ¥3,100


[Japan Activism/M&A] Thinking About the Partial Tender Trade Coming in Dec25

Japan

COSMOS Pharmaceutical Corporation operates drug stores based in Kyushu. The Company sells daily necessities such as drug medicines, foodstuffs, and alcoholic beverages.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cosmos Pharmaceutical (3349 JP)

Lung Fung Group (2290 HK): Still Looks Undervalued

Lung Fung announced that its retail sales revenue increased 21.2% in 1Q FY27, while same-store sales grew 10.3%. This is solid momentum, suggesting...

Osbert Tang, CFA

Cosmos (3349): Still Miles of Growth Runway

The market is discounting a rapid decay, but we still see another decade of above average growth and profitability. Margins are far more...

Michael Allen

Primer: Cosmos Pharmaceutical (3349 JP) - Aug 2026

Cosmos Pharmaceutical showcases a robust growth trajectory, underpinned by an aggressive store expansion strategy and a resilient "Everyday Low...

αSK Primers

Lung Fung Group (2290 HK) IPO: Too Cheap to Ignore

Lung Fung Group seeks to raise HK$672m in IPO, showing higher margins and profit compared to Sa Sa, with potential 29% upside at IPO price range.

Osbert Tang, CFA

[Japan Activism/M&A] Thinking About the Partial Tender Trade Coming in Dec25

Tsuruha and Welcia getting smacked late this AM and early PM - down 7% just now. This looks like an unwind of pre-positioned longs for the M _ _ _...

Travis Lundy

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Lung Fung Group (2290 HK): Still Looks Undervalued

Lung Fung announced that its retail sales revenue increased 21.2% in 1Q FY27, while same-store sales grew 10.3%. This is solid momentum, suggesting...

Osbert Tang, CFA

Cosmos (3349): Still Miles of Growth Runway

The market is discounting a rapid decay, but we still see another decade of above average growth and profitability. Margins are far more...

Michael Allen

Primer: Cosmos Pharmaceutical (3349 JP) - Aug 2026

Cosmos Pharmaceutical showcases a robust growth trajectory, underpinned by an aggressive store expansion strategy and a resilient "Everyday Low...

αSK Primers

Lung Fung Group (2290 HK) IPO: Too Cheap to Ignore

​Lung Fung Group seeks to raise HK$672m in IPO, showing higher margins and profit compared to Sa Sa, with potential 29% upside at IPO price range.

Osbert Tang, CFA

[Japan Activism/M&A] Thinking About the Partial Tender Trade Coming in Dec25

Tsuruha and Welcia getting smacked late this AM and early PM - down 7% just now. This looks like an unwind of pre-positioned longs for the M _ _ _...

Travis Lundy

Lung Fung Group seeks to raise HK$672m in IPO, showing higher margins and profit compared to Sa Sa, with potential 29% upside at IPO price range.